Nicotinic receptors and the treatment of attentional and cognitive deficits in neuropsychiatric disorders: Focus on the α7 nicotinic acetylcholine receptor as a promising drug target for schizophrenia

Central Nervous System Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2007, Pages 269-288

  Chiamulera, Christian ^a   Fumagalli, Guido ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

7 agonist; 7 nicotinic acetylcholine receptor; 7 positive allosteric modulator; Attention; Cognition; Neuropsychiatric disorders; Nicotine; Schizophrenia

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYL ISOXAZOL 3 YL) UREA; 1 AZABICYCLO[2.2.2]OCT 3 YL] 4 CHLOROBENZAMIDE; 2 (3 PYRIDYL) 1 AZABI CYCLO[3.2.2]NONANE; 3 (2,4 DIMETHOXYBENZYLIDENE) 3,4,5,6 TETRAHYDRO 2,3' BIPYRIDINE; 3' (5 CHLOROTHIOPHEN 2 YL)SPYRO 1 AZABICYCLO[2.2.2]OCTANE 3,5' [1' 3']OXAZOLIDIN 2 ONE; 4 (4 BROMOPHENYLOXYCARBONYL) 1,4 DIAZABICYCLO[3.2.2]NONANE; 5' PHENYLSPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' (3' H)FURO [2,3 B]PYRIDINE; ACP 104; ANABASINE DERIVATIVE; BUNGAROTOXIN RECEPTOR; CARBACHOL; CHOLINESTERASE INHIBITOR; GALANTAMINE; LY 2087101; MEM 3454; N (4 CHLOROPHENYL) [(4 CHLOROPHENYL)AMINO METHYLENE] 3 METHYL 5 ISOXAZOLEACETAMIDE; N [ 1 AZABICYCLO[2.2.2]OCT 3 YL] 7 [2 (METHOXY)PHENYL] 1 BENZOFURAN 2 CARBOXAMIDE; N [1 AZABICYCLO[2.2.2]OCT 3 YL]FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NORCLOZAPINE; OXAZOLIDINONE DERIVATIVE; PHA 543613; PHENCYCLIDINE; PHYSOSTIGMINE; PLACEBO; PNU 120596; PNU 282987; QUINUCLIDINE; QUINUCLIDINE DERIVATIVE; SEN WAYS; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,5' OXAZOLIDINE 2' ONE]; SSR 180711; TC 1698; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; ATTENTION; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; NAUSEA; NEUROPSYCHIATRY; NONHUMAN; QT PROLONGATION; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

EID: 37349120700     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152407783220797     Document Type: Review

References (188)

1. Monod, J.; Wyman, J.; Changeux, J.P. J. Mol. Biol., 1965, 12, 88-118.
2. Alkondon, M.; Pereira, E. F.; Cortes, W. S.; Maelicke, A.; Albuquerque, E. X. Eur. J. Neurosci., 1997, 9, 2734-42.
3. Bartus, R.T. Exp. Neurol., 2000, 163, 495-529.
4. Terry, A. V.; Buccafusco, J. J. J. Pharmacol. Exp. Ther., 2003, 306, 821-27.
5. Sarter, M.; Nelson, C.L.; Bruno, J.P. Schizophr. Bull., 2005, 31, 117-38.
6. Mazurov, A.; Hauser, T.; Miller, C.H. Curr. Med. Chem,. 2006, 13, 1567-84.
7. Sarter, M.; Parikh, V. Nat. Rev. Neurosci., 2005, 6, 48-56.
8. Damasio, A. R.; Graff-Radford, N. R.; Eslinger, P. J.; Damasio, H.; Kassell, N. Arch. Neurol., 1985, 42, 263-71.
9. Decker, M.W.; McGaugh, J.L. Synapse, 1991, 7, 151-68.
10. Semba, K. Behav. Brain Res., 2000, 115, 1117-41.
11. Cummings, J.L. Am. J. Geriatr. Psychiatry, 2003, 11, 131-45.
12. Ritchie, C.W.; Ames, D.; Clayton, T.; Lai, R. Am. J. Geriatr. Psychiatry, 2004, 12, 358-69.
13. Buccafusco, J.J. Mol. Interv., 2004, 4, 285-95.
14. Breese, C.R.; Lee, M.; Adams, C.E.; Sullivan, B.; Logel, J.; Gillen, K.M.; Marks, M.J.; Collins, A.C.; Leonard, S. Neuropsychopharmacology, 2000, 23, 351-64.
15. Freedman, R.; Adams, C.E.; Leonard, S. J. Chem. Neuroanat., 2000, 2, 299-306.
16. Crook, J.M.; Tomaskovic-Crook, E.; Copolov, D.L.; Dean, B. Am. J. Psychiatry, 2001, 158, 918-25.
17. Deutsch, J.A. Science, 1971, 174, 788-94.
18. Davies, M.A.; Compton-Toth, B.A.; Hufeisen, S.J.; Meltzer, H.Y.; Roth, B.L. Psychopharmacology, 2005, 178, 451-60.
19. Sur, C.; Mallorga, P.J.; Wittmann, M.; Jacobson, M.A.; Pascarella, D.; Williams, J.B.; Brandish, P.E.; Pettibone, D.J.; Scolnick, E.M.; Conn, P.J. Proc. Natl. Acad. Sci. USA, 2003,100, 13674-9.
20. Tandon, R.; Shipley, J.E.; Greden, J.F.; Mann, N.A.; Eisner, W.H.; Goodson, J.A. Schizophr. Res., 1991, 4, 23-30.
21. Tandon, R.; Greden, J.F. Arch. Gen. Psychiatry, 1989, 46, 745-53.
22. Karson, C.N.; Casanova, M.F.; Kleinman, J.E.; Griffin, W.S. Am. J. Psychiatry, 1993, 150, 454-59.
23. Karson, C.N.; Mrak, R.E.; Husain, M.M.; Griffin, W.S. Mol. Chem. Neuropathol., 1996, 29, 181-91.
24. Kirrane, R.M.; Mitroupoulou, V.; Nunn, M.; Silverman, J.; Siever, L.J. Schizophr. Res., 2001, 48, 1-5.
25. Chouinard, S.; Stip, E.; Poulin, J.; Melun, J.P.; Godbout, R.; Guillem, F.; Cohen, H. Curr. Med. Res. Opin. 2007, 23, 575-83.
26. Lenzi, A.; Maltinti, E.; Poggi, E.; Fabrizio, L.; Coli, E. Clin. Neuropharmacol., 2003, 26, 317-21.
27. MacEwan, G.W.; Ehmann, T.S.; Khanbhai, I.; Wrixon, C. Acta Psychiatr. Scand., 2001, 104, 469-72.
28. Friedman, J.I.; Adler, D.N.; Howanitz, E.; Harvey, P.D.; Brenner, G.; Temporini, H.; White, L.; Parrella, M.; Davis, K.L. Biol. Psychiatry, 2002, 5, 349-57.
29. Levin, E.D.; McClernon, F.J.; Rezvani, A.H. Psychopharmacology, 2006, 184, 523-39.
30. Mansvelder, H.D.; van Aerde, K.I.; Couey, J.J.; Brussaard, A.B. Psychopharmacology, 2006, 184, 292-305.
31. Levin, E.D.; Briggs, S.J.; Christopher, N.C.; Rose, J.E. Behav. Neural. Biol., 1992, 58, 152-8.
32. Elrod, K.; Buccafusco, J.J. Pharmacol. Biochem. Behav. 1988, 29, 15-21.
33. Newhouse, P.A.; Potter, A.; Corwin, J.; Lenox, R. Neuropsychopharmacology, 1994, 10, 93-107.
34. Heishman, S.J. Nicotine Tob. Res. 1999, 1(2), S143-7.
35. Adler, L.E.; Olincy, A.; Waldo, M.; Harris, J.G.; Griffith, J.; Stevens, K.; Flach, K.; Nagamoto, H.; Bickford, P.; Leonard, S.; Freedman, R. Schizophr. Bull., 1998, 24, 189-202.
36. Newhouse, P.A., Potter, A.; Singh, A. Curr. Opin. Pharmacol. 2004, 4, 36-46.
37. Depatie, L.; O'Driscoll, G.A.; Holahan, A.L.; Atkinson, V.; Thavundayil, J.X.; Kin, N.N.; Lal, S. Neuropsychopharmacology, 2002, 27, 1056-70.
38. Adler, L.E.; Hoffer, L.D.; Wise, A.; Freedman, R. Am. J. Psychiatry, 1993, 150, 1856-61.
39. Sacco, K.A.; Termine, A.; Seyal, A.; Dudas, M.M.; Vessicchio, J.C.; Krishnan-Sarin, S.; Jatlow, P.I.; Wexler, B.E.; George, T.P. Arch. Gen. Psychiatry, 2005, 62, 649-59.
40. George, T.P.; Termine, A.; Dudas, M.M.; Seyal, A.A.; Ludhi, T.; Bannon, K.; Vessicchio, J.C.; Madonick, S.H.; Sacco, K.A. Am. Coll. Neuropsychopharmacol., 2003, San Juan, Puerto Rico.
41. Levin, E.D.; Wilson, W.; Rose, J.E.; McEvoy, J. Neuropsychopharmacology, 1996a, 15, 429-36.
42. Levin, E.D.; Conners, C.K.; Sparrow, E.; Hinton, S.C.; Erhardt, D.; Meck, W.H.; Rose, J.E. Psychopharmacology, 1996b, 123, 55-63.
43. Rusted, J.M.; Caulfield, D.; King, L.; Goode, A. Behav. Pharmacol., 2000, 11, 621-9.
44. Picciotto, M. Trends Pharmacol. Sci., 2003, 24, 493-9.
45. Sacco, K.A.;. Bannon, K.L.; George, T.P. J. Psychopharmacol., 2004, 18, 457-74.
46. Waters, A.J.; Feyerabend, C. Psychol. Addict. Behav., 2000, 14, 111-20.
47. Stip, E.; Chouinard, S.; Boulay, L.J. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29, 219-32.
48. Green, M.F.; Nuechterlein, K.H.; Gold, J.M.; Barch, D.M.; Cohen, J.; Essock, S.; Fenton, W.S.; Frese, F.; Goldberg, T.E.; Heaton, R.K.; Keefe, R.S.; Kern, R.S.; Kraemer, H.; Stover, E.; Weinberger, D.R.; Zalcman, S.; Marder, S.R. Biol. Psychiatry, 2004, 56, 301-7.
49. Nuechterlein, K.H.; Barch, D.M.; Gold, J.M.; Goldberg, T.E.; Green, M.F.; Heaton, R.K. Schizophr. Res., 2004, 72, 29-39.
50. Venables, P. H. Ann. N.Y. Acad. Sci., 1992, 658, 111.
51. Adler, L.E.; Pachtman, E.; Franks, R.D.; Pecevich, M.; Waldo, M.C.; Freedman, R. Biol. Psychiatry, 1982, 17, 639-54.
52. Cullum, C.M.; Harris, J.G.; Waldo, M.C.; Smernoff, E.; Madison, A.; Nagamoto, H.T.; Griffith, J.; Adler, L.E.; Freedman, R. Schizophr. Res., 1993, 10,131-41.
53. Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; White, P.M. J. Abnorm. Psychol., 1998, 107, 691-8.
54. Luntz-Leybman, V.; Bickford, P.C.; Freedman, R. Brain Res., 1992, 587,130-6.
55. Bickford, P.C.; Wear, K.D. Brain Res., 1995, 705, 235-40.
56. Stevens, K.E.; Freedman, R.; Collins, A.C.; Hall, M.; Leonard, S.; Marks, M.J.; Rose, G.M. Neuropsychopharmacology, 1996, 15, 152-62.
57. Graham, F.K. Psychophysiology, 1975, 12, 238-48.
58. Swerdlow, N.R.; Braff, D.L.; Taaid, N.; Geyer, M.A. Arch. Gen. Psychiatry, 1994, 51, 139-54.
59. Braff, D.L.; Geyer, M.A.; Swerdlow, N.R. Psychopharmacology, 2001, 156, 234-58.
60. Perry, W.; Braff, D.L. Am. J. Psychiatry, 1994, 151, 363-7.
61. Kumari, V.; Soni, W.; Sharma, T. Hum. Psychopharm. Clin. Exp., 2001, 16, 321-6.
62. Spielewoy, C.; Markou, A. Behav. Genet., 2004, 34, 343-54.
63. Javitt, D.C.; Zukin, S.R. Am. J. Psychiatry, 1991, 148, 1301-18.
64. Anokhin, A.P.; Heath, A.C.; Myers, E.; Ralano, A.; Wood, S. Neurosci. Lett., 2003, 353, 45-8.
65. Geyer, M.A.; McIlwain, K.L.; Paylor, R. Mol. Psychiatr., 2002,7,1039-53.
66. Kumari, V.; Gray, J.A.; ffytche, D.; Mitterschiffthaler, M.T.; Das, M.; Zachariah, E.; Vythelingum, G.N.; Williams, S.C.R.; Simmons, A.; Sharma, T. NeuroImage, 2003, 19, 1002-13.
67. Ettinger, U.; Kumari, V. Curr. Neuropharmacol., 2003, 1, 285-300.
68. Bullock, A.E.; Slobe, B.S.; Vázquez, V.; Collins, A.C. Behav. Neurosci., 1997, 111, 1353-60.
69. Stevens, K.E.; Wear, K.D. Pharmacol. Biochem. Behav., 1997, 57, 869-74.
70. Freedman, R.; Coon, H.; Myles-Worsley, M.; Orr-Urtreger, A.; Olincy, A.; Davis, A.; Polymeropoulos, M.; Holik, J.; Hopkins, J.; Hoff, M.; Rosenthal, J.; Waldo, M.C.; Reimherr, F.; Wender, P.; Yaw, J.; Young, D.A., Breese, C.R.; Adams, C.E.; Patterson, D.; Adler, L.E.; Kruglyak, L.; Leonard, S.; Byerley, W. Proc. Natl. Acad. Sci. USA, 1997, 94, 587-92.
71. Leonard, S.; Gault, J.; Hopkins, J.; Logel, J.; Vianzon, R.; Short, M.; Drebing, C.; Berger, R.; Venn, D.; Sirota, P.; Zerbe, G.O.; Olincy, A.; Ross, R.G.; Adler, L.E.; Freedman, R. Arch. Gen. Psychiatry, 2002, 59, 1085-96.
72. Kumari, V.; Postma, P. Neurosci. Biobehav. Rev., 2005, 29, 1021-34.
73. Freedman, R.; Hall, M.; Adler, L.E.; Leonard, S. Biol. Psychiatry, 1995, 38, 22-33.
74. Court, J.; Spurden, D.; Lloyd, S.; McKeith, I.; Ballard, C.; Cairns, N.; Kerwin, R.; Perry, R.; Perry, E. J. Neurochem., 1999, 73,1590-97.
75. Guan, Z.Z.; Zhang, X.; Blennow, K.; Nordberg, A. Neuroreport, 1999, 10, 1779-82.
76. Marutle, A.; Zhang, X.; Court, J.; Piggot, M.; Johnson, M.; Perry, R.; Perry, E.; Nordberg, A. J. Chem. Neuroanat., 2001, 22,115-26.
77. Dalack, G.W.; Healy, D.J.; Meador-Woodruff, J.H. Am. J. Psychiatry, 1998, 155, 1490-501.
78. Taiminen, T.J.; Salokangas, R.K.R.; Saarijarvi, S.; Niemi, H.; Lehto, H.;Ahola, V.; Syvalahti, E. Addict. Behav., 1998, 23, 263-6.
79. Martin, L.F.; Kem, W.R.; Freedman, R. Psychopharmacology, 2004, 174, 54-64.
80. Rezvani, A.H.; Levin, E.D. Biol. Psychiatry, 2001, 49, 258-67.
81. Yang, Y.K.; Nelson, L.; Kamaraju, L.; Wilson, W.; McEvoy, J.P. Neuropsychopharmacology, 2002, 27, 684-6.
82. Dalack, G.W.; Becks, L.; Hill, E.; Pomerleau, O.F.; Meador-Woodruff, J.H.; Neuropsychopharmacology, 1999, 21, 1995-2002.
83. Smith, R.C.; Singh, A.; Infante, M.; Khandat, A.; Kloos, A. Neuropsychopharmacology, 2002, 27, 479-97.
84. Clarke, P.B.; Pert, C.B.; Pert, A. Brain Res., 1984, 323, 390-5.
85. Freedman, R.; Wetmore, C.; Stromberg, I.; Leonard, S.; Olson, L. J. Neurosci., 1993, 13, 1965-75.
86. Sarter, M.; Givens, B.; Bruno, J.P. Brain Res. Brain Res. Rev. 2001, 35, 146-60.
87. Kristensen, S.E.; Thomsen, M.S.; Hansen, H.H.; Timmermann, D.B.; Hay-Schmidt, A.; Mikkelsen, J.D. Neurosci. Lett., 2007, 418, 154-8.
88. Hansen, H.H.; Timmermann, D.B.; Peters, D.; Walters, C.; Damaj, M.I.; Mikkelsen, J.D. J. Neurosci. Res., 2007, 85, 1810-8.
89. Fink-Jensen, A.; Kristensen, P. Neurosci. Lett., 1994, 182,115-8.
90. Arnt, J.; Skarsfeldt, T. Neuropsychopharmacology, 1998, 18,63-101.
91. Jensen, A.A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. J. Med. Chem., 2005, 48, 4705-45.
92. Kem, W. R.; Mahnir, V. M.; Prokai, L.; Papke, R. L.; Cao, X.; LeFrancois, S.; Wildeboer, K.; Prokai-Tatrai, K.; Porter-Papke, J.; Soti, F. Mol. Pharmacol., 2004, 65, 56-67.
93. de Fiebre, C. M.; Meyer, E. M.; Henry, J. C.; Muraskin, S. I.; Kem, W. R.; Papke, R. L. Mol. Pharmacol., 1995, 47, 164.
94. Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Curr. Top. Med. Chem. 2004, 4, 299.
95. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J., 3rd; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. J. Med. Chem., 2000, 43, 4045.
96. Broad, L.M.; Felthouse, C.; Zwart, R.; McPhie, G.I.; Pearson, K.H.; Craig, P.J.; Wallace, L.; Broadmore, R.J.; Boot, J.R.; Keenan, M.; Baker, S.R.; Sher, E. Eur. J. Pharmacol. 2002, 452, 137-44.
97. Astles, P. C.; Baker, S. R.; Boot, J. R.; Broad, L. M.; Dell, C. P.; Keenan, M. Curr. Drug Targets: CNS Neurol. Disord., 2002, 1, 337-48.
98. Bodnar, A. L.; Cortes-Burgos, L. A.; Cook, K. K.; Dinh, D. M.; Groppi, V. E.; Hajos, M.; Higdon, N. R.; Hoffmann, W. E.; Hurst, R. S.; Myers, J. K.; Rogers, B. N.; Wall, T. M.; Wolfe, M. L.; Wong, E. J. Med. Chem., 2005, 48, 905-8.
99. Tatsumi, R.; Fujio, M.; Satoh, H.; Katayama, J.; Takanashi, S.; Hashimoto, K.; Tanaka, H. J. Med. Chem., 2005, 48, 2678-86.
100. Wishka, D.G.; Walker, D.P.; Yates, K.M.; Reitz, S.C.; Jia, S.; Myers, J.K.; Olson, K.L.; Jacobsen, E.J.; Wolfe, M.L. Groppi, V.E.; Hanchar, A.J.; Thornburgh. B.A.; Cortes-Burgos, L.A.; Wong, E.H.; Staton, B.A.; Raub, T.J.; Higdon, N.R.; Wall, T.M.; Hurst, R.S.; Walters, R.R.; Hoffmann, W.E.; Hajos, M.; Franklin, S.; Carey, G.; Gold, L.H.; Cook, K.K.; Sands, S.B.; Zhao, S.X.; Soglia, J.R.; Kalgutkar, A.S.; Arneric, S.P.; Rogers, B.N. J. Med. Chem., 2006, 49, 4425-36.
101. Meyer, E. M.; Kuryatov, A.; Gerzanich, V.; Lindstrom, J.; Papke, R. L. J. Pharmacol. Exp. Ther., 1998, 287, 918-25.
102. Stokes, C.; Papke, J. K.; Horenstein, N. A.; Kem, W. R.; McCormack, T. J.; Papke, R. L. Mol. Pharmacol., 2004, 66, 14-24.
103. Stevens, K. E.; Kem, W. R.; Mahnir, V. M.; Freedman, R. Psychopharmacology, 1998, 136, 320-7.
104. Stevens, K.E.; Kem, W.R.; Freedman, R. Biol. Psychiatry, 1999, 46,1443-50.
105. Olivier, B.; Leahy, C.; Mullen, T.; Paylor, R.; Groppi, V.E.; Sarnyai, Z.; Brunner, D. Psychopharmacology, 2001, 156, 284-90.
106. Simosky, J.K.; Stevens, K.E.; Kem, W.R.; Freedman, R. Biol. Psychiatry, 2001, 50, 493-500.
107. Schreiber, R.; Dalmus, M.; De Vry, J. Psychopharmacology, 2002, 159, 248-57.
108. Arendash, G.W.; Sengstock, G.J.; Sanberg, P.R.; Kem, W.R. Brain Res., 1995, 674, 252-9.
109. Meyer, E.M.; Tay, E.T.; Papke, R.L.; Meyers, C.; Huang, G.l.; De Fiebre, C.M. Brain Res., 1997, 768, 49-56.
110. Meyer, E.M.; Tay, E.T.; Zoltewicz, J.A.; Meyers, C.; King, M.A.; Papke, R.L.; De Fiebre, C.M. J. Pharmacol. Exp. Ther., 1998, 284, 1026-32.
111. Woodruff-Pak, D.S.; Li, Y.T.; Kem, W.R. Brain Res., 1994, 645, 309-17.
112. Woodruff-Pak, D.S. Behav. Brain Res., 2003, 143, 159-67.
113. Briggs, C.A.; Anderson, D.J.; Brioni, J.D.; Buccafusco, J.J.; Buckley, M.J.; Campbell, J.E.; Decker, M.W.; Donelly-Roberts, D.; Elliott, R.L.; Gopalakrishnan, M.; Holladay, M.W.; Hui, Y-H.; Jackson, W.J.; Kim, D.J.B.; Marsh, K.C.; O'Neill, A.; Prendergast, M.A.; Ryther, K.B.; Sullivan, J.P.; Arneric, S.P. Pharmacol. Biochem. Behav., 1997, 57, 231-241.
114. van Haaren, F.; Anderson, K.G.; Haworth, S.C.; Kem, W.R. Pharmacol. Biochem. Behav., 1999, 64, 439-44.
115. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K.A.; Kramer, W.G.;Clody, D.E.; Burnett, A.L. Neuropsychopharmacology, 2003, 28, 542-51.
116. Olincy, A.; Harris, J.G.; Johnson, L.L.; Pender, V.; Kongs, S.; Allensworth, D.; Ellis, J.; Zerbe, G.O.; Leonard, S.; Stevens, K.E.; Stevens, J.O.; Martin, L.; Adler, L.E.; Soti, F.; Kem, W.R.; Freedman, R. Arch. Gen. Psychiatry, 2006, 63, 630-8.
117. Papke, R. L.; Porter Papke, J. K.; Rose, G. M. Bioorg. Med. Chem. Lett., 2004, 14, 49-53.
118. Grottick, A. J.; Higgins, G. A. Behav. Brain Res., 2000, 117, 197-208.
119. Grottick, A. J.; Haman, M.; Wyler, R.; Higgins, G.A. Neuropsychopharmacology, 2003, 28, 880-7.
120. Hahn, B.; Sharples, C. G.; Wonnacott, S.; Shoaib, M.; Stolerman, I. P. Neuropharmacology, 2003, 44, 1054-67.
121. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. Psychopharmacology, 2004, 172, 375-83.
122. Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. Behav. Pharmacol., 1999, 10, 675-80.
123. Grottick, A.J., Wyler, R., Higgins, G. Psychopharmacology, 2000a, 150,233-6.
124. Grottick, A.J.; Trube, G.; Corrigal, W.A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G.A. J. Pharmacol. Exp. Ther., 2000b, 294,1112-9.
125. Hajos, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. J. Pharmacol. Exp. Ther., 2005, 312, 13-22.
126. Shaffer, C.L.; Gunduz, M.; Scialis, R.J.; Fang, A.F. Drug Metab. Dispos., 2007, 35, 1188-95.
127. Biton, B.; Bergis, O.E.; Galli, F.; Nedelec, A.; Lochead, A.W.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney. F.; Leonardon, J.; Granger, P.; Debono, M.W.; Bohme, G.A.; Sgard, F.; Besnard, F; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vige, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Francon, D.; Steinberg, R; Griebel, G.; Oury-Donat, F.; George, P.; Avenet, P.; Scatton, B. Neuropsychopharmacology, 2007,32, 1-16.
128. Pichat, P.; Bergis, O.E.; Terranova, J.P.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. Neuropsychopharmacology, 2007, 32, 17-34.
129. Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. Biol. Psychiatry, 2007, Jun 27 [Epub ahead of print].
130. Boess, F.G.; De Vry, J.; Erb, C.; Flessner, T.; Hendrix, M.; Luithle, J.; Methfessel, C.; Riedl, B.; Schnizler, K.; van der Staay, F.J.; van Kampen, M.; Wiese, W.B.; Koenig, G. J. Pharmacol. Exp. Ther., 2007, 321, 716-25.
131. Shaw, S.; Bencherif, M.; Marrero, M.B. J. Biol. Chem.,2002, 277, 44920-4.
132. Marrero, M. B.; Papke, R. L.; Bhatti, B. S.; Shaw, S.; Bencherif, M. J. Pharmacol. Exp. Ther., 2003, 309, 16-27.
133. Wang, S.; Michael, T.; Dragan, S.; Sun, S.; Xiao, Q.; Callahan, P.M.; Xie, W.; Herbert, B.;. Graham, E; De Vivo, M.; Tehim A. Program No. 163.2. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
134. Huang, M.; Prus, A.J.; Li, Z.; Dai, J.; Callahan, P.M.; Meltzer, H.Y. Program No. 163.1. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
135. Rezvani, H.; Kholdebarin, E.; Brucato, F.H.; Callahan, P.M.; Levin, E.D. Program No. 163.3. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
136. Roncarati, R.; Bothmann, H.; Diadato, E.; Jow, B.; Lock, T.; Lin, S.S.; Dunlop, J.; Varrone, M.; Ghiron, C.; Gaviraghi, G.; Caricasole, A.; Terstappen, G. Program No. 524.7. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
137. Scali, C.; Gianfriddo, M.; Zanelli, U.; Kelley, C.; Logue, S.F.; Haydar, S.; Lin, S.S.; Dunlop, J.; Terstappen, G.C.; Caricasole, A.; Roncarati, R. Program No. 524.5. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
138. Logue, S.F.; Grauer, S.M.; Scali, C.; Roncarati, R.; Marquis, K.L.; Haydar, S.N.; Lin, S.; Dunlop, J. Program No. 94.13. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
139. De Filippi, G.; Broad, L.M.; Zwart, R.; Baldwinson, T.; Felthouse, C.; McPhie, G.; Pearson, K.; Craig, P.; Broadmore, R.; Bell, E.; Cases, M.; Keenan, M.; Baker, S.R.; Boot, J.; Sher.E. Program No. 137.5. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online.
140. O'Neill, M.J.; Moore, N.A.; McKinzie, D.L.; Keenan, M.; Wishart, G.; Shannon, H.E.; Murray, T.K.; O'Neill, M.F.; Tree, B.; Iyengar, S.; Hart, J.; Shaw, D.; Simmons, R.M.A.; Kalra, A.B.; Miles C.; Baker, S.R.; Sher, E.; Tricklebank, M.D. Program No. 137.6. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online.
141. Cilia, J.; Cluderay, J.E.; Robbins, M.J.; Reavill, C.; Southam, E.; Kew, J.N.; Jones, D.N. Psychopharmacology, 2005, 182, 214-9.
142. Krause, R.M.; Buisson, B.; Bertrand, S.; Corringer, P.J.; Galzi, J.L.; Changeux, J.P.; Bertrand, D. Mol. Pharmacol., 1998, 53, 283-94.
143. Maelicke, A. Dement. Geriatr. Cogn. Disord., 2000, 11, 11-8.
144. Zwart, R.; De Filippi, G.; Broad, L.M.; McPhie, G.I.; Pearson, K.H., Baldwinson, T.; Sher, E. Neuropharmacology, 2002, 43, 374-84.
145. Hurst, R.S.; Hajós, M.; Raggenbass, M.; Wall, T.M.; Higdon, N.R.; Lawson, J.A.; Rutherford-Root, K.L.; Berkenpas, M.B.; Hoffmann, W.E.; Piotrowski, D.W.; Groppi, V.E.; Allaman, G.; Ogier, R.; Bertrand, S.; Bertrand, D.; Arneric, S. J. Neurosci., 2005, 25, 4396-405.
146. Ng, H.J.; Whittemore, E.R.; Tran, M.B.; Hogenkamp, D.J.; Broide, R.S.; Johnstone, T.B.; Zheng, L.; Stevens, K.E.; Gee, K.W. Proc. Natl. Acad. Sci. USA, 2007, 104, 8059-64.
147. Broad, L.M.; Zwart, R.; Pearson, K.H.; Lee, M.; Wallace, L.; McPhie, G.I.; Emkey, R.; Hollinshead, S.P.; Dell, C.P.; Baker, S.R.; Sher, E. J. Pharmacol. Exp. Ther., 2006, 318, 1108-17.
148. Dani, J.A.; Heinemann, S. Neuron, 1996, 16, 905-8.
149. Cassels, B.K.; Bermudez, I.; Dajas, F.; Abin-Carriquiry, J.A.; Wonnacott, S. Drug Discov. Today, 2005, 10, 1657-65.
150. Quick, M.W.; Lestere, R.A. J. Neurobiol., 2002, 53, 457-78.
151. Revah, F.; Bertrand, D.; Galzi, J.L.; Devillers-Thiery, A.; Mulle, C.; Hussy, N.; Bertrand, S.; Ballivet, M.; Changeux, J.P. Nature, 1991, 353, 846-9.
152. Eisele, J.L.; Bertrand, S.; Galzi, J.-L.; Devillers-Thiery, A.; Changeux, J.-P.; Bertrand, D. Nature,1993, 366, 479-483.
153. Hogg, R.C.; Bertrand, D. Science, 2004, 306, 983-5.
154. Craig, P.J.; Bose, S.; Zwart, R.; Beattie, R.E.; Folly, E.A.; Johnson, L.R.; Bell, E.; Evans, N.M.; Benedetti, G.; Pearson, K.H.; McPhie, G.I.; Volsen, S.G.; Millar, N.S.; Sher, E.; Broad, L.M. Eur. J. Pharmacol., 2004, 502, 31-40.
155. Bertrand, D.; Devillers-Thiery, A.; Revah, F.; Galzi, J.L.; Hussy, N.; Mulle, C.; Bertrand, S.; Ballivet, M.; Changeux, J.P. Proc. Natl. Acad. Sci. USA, 1992, 89, 1261-5.
156. Lukas, R.J.; Lucero, L.; Buisson, B.; Galzi, J.L.; Puchacz, E.; Fryer, J.D.; Changeux, J.P.; Bertrand, D. Eur. J. Neurosci., 2001, 13, 1849-60.
157. Kem, W. R.; Mahnir, V. M.; Papke, R. L.; Lingle, C. J. J. Pharmacol. Exp. Ther., 1997, 283, 979.
158. Levin, E.D.; Rezvani, A.H. Eur. J. Pharmacol., 2000, 393, 141-146.
159. Macor, J. E.; Gurley, D.; Lanthorn, T.; Loch, J.; Mack, R. A.; Mullen, G.; Tran, O.; Wright, N.; Gordon, J. C. Bioorg. Med. Chem. Lett., 2001, 11, 319-21.
160. Gurley, D.A.; Lanthorn, T.H. Neurosci. Lett., 1998,247,107-10.
161. Machu, T. K.; Hamilton, M. E.; Frye, T. F.; Shanklin, C. L.; Harris, M. C.; Sun, H.; Tenner, T. E., Jr.; Soti, F. S.; Kem, W. R. J. Pharmacol. Exp. Ther., 2001, 299, 1112-9.
162. Robbins, T.W. Schizophr. Bull., 2005, 31, 854-64.
163. Hyman, S.E.; Fenton, W.S. Science, 2003, 299, 350-1.
164. Simosky, J.K.; Stevens, K.E.; Adler, L.E.; Freedman, E.F. Psychopharmacology, 2003, 165, 386-96.
165. Maxwell, C.R.; Liang, Y.; Weightman, B.D.; Kanes, S.J.; Abel, T.; Gur, R.E.; Turetsky, B.I.; Bilker, W.B.; Lenox, R.H.; Siegel, S.J. Neuropsychopharmacology, 2004, 29, 739-46.
166. Ellenbroek, B.A. Psychopharmacology, 2004,174,65-74.
167. Geyer, M.A.; Krebs-Thomson, K.; Braff, D.L.; Swerdlow, N.R. Psychopharmacology, 2001, 156,117-54.
168. Geyer, M.A.; Ellenbroek, B.A. Prog. Neuropsychoph., 2003, 27,1071-9.
169. Robbins, T.W. Psychopharmacology, 2002,163,362-80.
170. Wexler, B.E.; Nicholls, S.S.; Bell, M.D. Schizophr. Res., 2004, 71,513-4.
171. Mishara, A.L.; Goldbert, T.E. Biol. Psychiat., 2004, 55, 1013-22.
172. Keefe, R.S.E. Silva, S.G.; Perkins, D.O.; Lieberman, J.A. Schizophr. Bull.,1999, 25, 201-22.
173. Harvey, P.D.; Keefe, R.S.E. Am. J. Psychiatry, 2001, 158, 176-84.
174. Hagan, J.J.; Jones, D.N. Schizophr. Bull., 2005, 31, 830-53.
175. Robbins, T.W. Behav. Pharmacol.,1998, 9, 509-19.
176. Sarter, M. Trends Pharmacol. Sci., 2006, 27, 602-8.
177. Kapur, S.; Wadenberg, M.L.; Remington, G. Can. J. Psychiat., 2000,45,241-6.
178. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Nat. Rev. Mol. Cell. Biol., 2003, 4, 552-65.
179. Orr-Urtreger, A.; Broide, R.S.; Kasten, M.R.; Dang, H.; Dani, J.A.; Beaudet, A.L.; Patrick, J.W. J. Neurochem., 2000, 74, 2154-66.
180. Damaj, M.I.; Glassco, W.; Dukat, M.; Martin, B.R. J. Pharmacol. Exp. Ther., 1999, 291, 1284-91.
181. Stolerman, I. Behav Pharmacol., 1999, 10, 559-80.
182. Sirota, P.; Mosheva, T.; Shabtay, H.; Giladi, N.; Korczyn, A. D. Am. J. Psychiatry, 2000, 157, 287-9.
183. Hashimoto, K.; Fujita, Y.; Ishima, T.; Hagiwara, H; Iyo, M. Eur. J. Pharmacol., 2006, 553, 191-5.
184. Hashimoto, K.; Iyo, Y.; Freedman, R.; Stevens, K.E. Psychopharmacology, 2005, 183, 13-9.
185. Koike, K.; Hashimoto, K.; Takai, N.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Nakazato, M.; Okamura, N.; Stevens, K.E.; Freedman, R.; Iyo, M. Schizophr. Res., 2005, 76, 67-72.
186. Carter, C.S. Schizophr Bull., 2005, 31, 810-5.
187. Chiamulera, C. Brain Res. Rev., 2005, 48, 74-97.
188. Pangalos, M.N.; Schechter, L.E.; Hurko, O. Nat. Rev. Drug Discov., 2007, 6, 521-32.